Pamish

Pamish has signed a contract with Thermo Fisher Scientific to supply nucleoside pharmaceutical intermediates worth 1.347 billion KRW. The contract runs until August 14, 2020.

Pamish has signed a 6-year supply contract with Belgian pharmaceutical company UCB to provide mPEG-20k, a raw material for UCB's autoimmune disease drug Cimzia. The contract is effective from January 23, 2017, with automatic annual renewals thereafter.